Novabay Pharmaceuticals 

€0
91
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Sep 25
€3.4
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7MayExpected
Q3 2025
Next
-0.99
-0.95
-0.91
-0.87
Expected EPS
-0.86873
Actual EPS
N/A

Financials

-87.8%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
18.55MRevenue
-16.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B9P1.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ocular Therapeutix
OCUL
Mkt Cap1.85B
Ocular Therapeutix focuses on developing treatments for eye diseases, directly competing with Novabay's eye care products.
National Vision
EYE
Mkt Cap2.09B
National Vision Holdings operates in the eye care market, offering products that can be seen as alternatives to Novabay's offerings.
Alcon
ALC
Mkt Cap37.27B
Alcon specializes in eye care products, including surgical, vision care, and ophthalmic pharmaceuticals, competing across several of Novabay's key areas.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its Vision Care division, competes in the eye health sector, offering products that rival Novabay's.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad range of healthcare products, including treatments for eye conditions that compete with Novabay's pharmaceuticals.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a wide range of healthcare products, including ophthalmic solutions that compete with Novabay's eye care products.
Bausch Health Companies
BHC
Mkt Cap1.99B
Bausch Health Companies, through its eye health division, directly competes with Novabay in the ophthalmology and optometry markets.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is involved in developing treatments for eye diseases, offering products that compete with Novabay's portfolio.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie, having acquired Allergan, competes in the eye care sector with a portfolio that includes treatments for various eye conditions, challenging Novabay's market share.

About

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Show more...
CEO
ISIN
US66987P5089
WKN
000A422LL

Listings

0 Comments

Share your thoughts

FAQ

What is Novabay Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Novabay Pharmaceuticals stocks are traded under the ticker B9P1.F.
When is the next Novabay Pharmaceuticals earnings date?
Novabay Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Novabay Pharmaceuticals earnings last quarter?
B9P1.F earnings for the last quarter are -0.99 EUR per share, whereas the estimation was -0.91 EUR resulting in a -9.52% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Novabay Pharmaceuticals revenue for the last year?
Novabay Pharmaceuticals revenue for the last year amounts to 18.55M EUR.
What is Novabay Pharmaceuticals net income for the last year?
B9P1.F net income for the last year is -16.29M EUR.
Does Novabay Pharmaceuticals pay dividends?
Yes, B9P1.F dividends are paid en. The last dividend per share was 3.4 EUR. As of today, Dividend Yield (FWD)% is 0%.
When did Novabay Pharmaceuticals complete a stock split?
The last stock split for Novabay Pharmaceuticals was on February 23, 2026 with a ratio of 1:5.